LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Phase 2
Completed
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Drug: LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU
- Registration Number
- NCT00610883
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Brief Summary
Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months. To aggressively treat this cancer this study uses effective drugs in three parts:
* Induction ends on day 19
* Consolidation ends on day 38 or 42
* Maintenance may include up to 6 cycles
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 17
Inclusion Criteria
-
Non-Hodgkin's Lymphoma stages III, IV, IVA with
- T cell lymphomas, any primary site irrespective of LDH level
- large cell lymphomas, any primary site irrespective of LDH level
- B cell lymphomas, any primary site with initial LDH of less than 500
Read More
Exclusion Criteria
- B cell lymphomas, any primary site with initial LDH of less than 500 and initial CNS or bone involvement
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 - LSA4 LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU -
- Primary Outcome Measures
Name Time Method Complete Remission 330 Days The number of patients who achieved a complete remission as a result of treatment
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Memorial Sloan-Kettering Cancer Center
🇺🇸New York, New York, United States